GlaxoSmithKline Partnering with Exscientia

GlaxoSmithKline is partnering with privately-owned Exscientia to use artificial intelligence to help develop new drugs, according to a report from Reuters.

The deal with Exscientia will allow GlaxoSmithKline to search drug candidates for up to 10 disease-related targets by using super computers and machine-learning systems to predict how molecules will behave. Exscientia’s artificial intelligence system could deliver drug candidates in “roughly one-quarter of the time and at one-quarter of the cost,” said Exscientia CEO Andrew Hopkins. GSK will provide research funding and make payments of GBP33 million ($43 million), if pre-clinical milestones are met.

Leave a Comment